Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237105 | 0.84 | HSD11B1 (0.72) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216344 | 0.83 | HSD11B1 (1.00) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216447 | 0.82 | HSD11B1 (0.69) | HSD11B1 | |
| SCHEMBL3025215 | 0.81 | HSD11B1 (0.73) | HSD11B1MEN1KMT2A | |
| SCHEMBL7813280 | 0.80 | HSD11B1 (1.00) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216326 | 0.80 | HSD11B1 (1.00) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216106 | 0.80 | HSD11B1 (0.71) | HSD11B1MEN1KMT2A | |
| SCHEMBL3023608 | 0.77 | HSD11B1 (0.72) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216108 | 0.76 | HSD11B1 (0.65) | HSD11B1MEN1KMT2A | |
| SCHEMBL13216630 | 0.72 | HSD11B1 (0.77) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054368-B1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2054368-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| WO-2008024892-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024892-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885 |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.